If You Invested in Point Biopharma Global Inc (PNT)
Looking for the current price? See the PNT quote & overviewWhat $1,000 or $10,000 in PNT Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 9, 2020 |
|---|---|---|---|---|
| $1,000 | — | $1,566 +57% | — | $909 -9% |
| $10,000 | — | $15,664 +57% | — | $9,094 -9% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2023-12-29. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for PNT$1,000 Investment Over Time
PNT vs S&P 500Year-by-Year Returns
PNT annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2020 | $13.74 | $13.92 | +1.3% | +1.3% |
| 2021 | $13.92 | $5.60 | -59.8% | -59.3% |
| 2022 | $5.60 | $7.29 | +30.2% | -47.0% |
| 2023 | $7.29 | $12.50 | +71.5% | -9.1% |
About Point Biopharma Global Inc
NASDAQ
Frequently Asked Questions
Point Biopharma Global Inc investment returns
How much would $1,000 invested in Point Biopharma Global Inc be worth today?
If you invested $1,000 in Point Biopharma Global Inc (PNT) 5 years ago on 2021-10-29, your investment would be worth $1,566 as of 2023-12-29, a +56.6% price return without dividends, growing at a compounded rate of 23.0% per year (CAGR).
Has Point Biopharma Global Inc outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare PNT performance over available time periods.
What is Point Biopharma Global Inc's average annual return?
The compound annual growth rate (CAGR) of PNT’s share price over the past 5 years is 23.0%, without dividends. Individual years vary a great deal, and PNT’s best recent full year was 2023 (+71.5%) while the worst was 2021 (-59.8%).
For informational and educational purposes only, not investment advice.
